Developed by Theratechnologies Inc., it underwent phase II trials in the mid-2000s for GH deficiency (GHD) and HIV lipodystrophy but was discontinued, with reported reasons including hypersensitivity reactions, including an anaphylaxis-like reaction in one trial participant Wong et al (2008) [Note: Abstract only
Further, persons with recent incarceration were about half as likely (0.53 times) as those without recent incarceration to die of opioids in combination with other non-stimulant substances, versus opioids alone
Critical Reviews on Toxicology 23(1):2148 Kielstein J, Bode-Boger S, Klein G, Graf S, Haller H, Fliser D (2003) Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure
When you're already overwhelmed, keeping track of a complex supplement regimen can feel impossible
Market Opportunity: Advancements in dual and triple agonist therapies acts as an opportunity for the GLP-1 Receptor Agonist market